Niagen Bioscience Reports Third-Quarter 2026 Financial Results
Niagen Bioscience reported financial results for the third quarter of 2026; the supplied body is truncated before any figures or details.
Story updates
09:05:15 PM UTC
SquawkNews
Launched Niagen™ Plus Niagen™ Liquid At-Home Injections Launched Niagen NanoCloud™, the first dermat
09:13:29 PM UTC
SquawkNews
Niagen Bioscience reported third-quarter 2026 revenue of $27.19M, down 20% from the prior-year quarter, and a net loss of $1.17M compared with net income of $4.58M a year earlier. Diluted EPS was a loss of $0.01, versus earnings of $0.05 per share.Financial Highlights¹ Reported as “Sales, net”. ² R…
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its operational updates and financial results for the third quarter of 2026.Third Quarter 2026 Financial and Business Highlights“Duri…